Drug Discovery World
MARCH 7, 2023
The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are developing therapies that employ plasmids (circular DNA encoding a gene called p62/SQSTM1).
The Pharma Data
DECEMBER 23, 2020
” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
FEBRUARY 27, 2024
Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.
Roots Analysis
FEBRUARY 21, 2022
Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. During our research, we came across more than 55 players, which claim to offer 280+ NGS library preparation kits. Nanoparticles Contract Manufacturing.
The Pharma Data
SEPTEMBER 11, 2021
Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We Twist and Boehringer Ingelheim will work together to validate and optimize any resulting new antibody candidates, which could be researched against a range of therapeutic areas. Wood, Ph.D., Leproust, Ph.D., CEO and co-founder of Twist.
Roots Analysis
FEBRUARY 18, 2022
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.
Roots Analysis
JUNE 30, 2023
We’ve also done a detailed market research report on digital biomanufacturing. Download Full Whitepaper References: 90% of drugs fail clinical trials – here’s one way researchers can select better drug candidates, 2022 [link] How digital solutions are transforming biomanufacturing, 2022?
Expert insights. Personalized for you.
52 
Let's personalize your content